Data. by Saeedeh Abbasi (9423189)

Subjects:

Effect of aging on cellular senescence in the mouse kidney. by Lihua Qiu (178071)

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

Determination of Cleaved Caspase-3 positive cells in MTA and Harvard treated groups. by Meltem Karahan (19713246)

Subjects:

Dose-dependent effect of dental materials on hatching rate of zebrafish embryos and larvae at the indicated time points. by Meltem Karahan (19713246)

Subjects:

Dose-dependent effect of dental materials on the survival of zebrafish embryos and larvae at the indicated time points. by Meltem Karahan (19713246)

Subjects:

The apoptic effects of dental materials on zebrafish larvae. by Meltem Karahan (19713246)

Subjects:

The normal force between two particles with De = 6.30 mm for different aspect ratios and sphericities: (a) hertz normal contact force; (b) normal viscous contact force. by Yongfeng Zhu (7361045)

Subjects:

The tangential force between two particles with different aspect ratios and sphericities for De = 6.30 mm: (a) elastic tangential contact force; (b) viscous tangential contact forc... by Yongfeng Zhu (7361045)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

The PP1/PP2A inhibitor calyculin A increases phosphorylated Ser295 of PSD-95 concomitantly with the activation of JNK1. by Takahiko Chimura (729098)